加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.1782
−US$0.0364 · -16.96%
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
收盘时
US$0.1782
−US$0.0364 · -16.96%
盘后
US$0.18
+US$0.0018 · +1.01%
10月12日 19:50 ET
盘中时间采用ET。市场数据可能有所延迟。
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
日内区间
当前US$0.1782
52周区间
当前US$0.1782
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
53
多空交织
风险
63
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
日内区间
当前US$0.1782
52周区间
当前US$0.1782
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 714万 USD | 581.5万 USD | 370.8万 USD | 322.6万 USD | — |
| 销售、一般及管理费用 | 447.8万 USD | 673.1万 USD | 92.8万 USD | 57.7万 USD | 94.39万 USD |
| 营业费用 | −1163.2万 USD | 1257.1万 USD | 468.1万 USD | 386万 USD | 94.39万 USD |
| 利息收入 | 14.2万 USD | 1000 USD | 15.3万 USD | 11.4万 USD | 6372 USD |
| 利息支出 | 1.3万 USD | 5.2万 USD | 9000 USD | 8.5万 USD | — |
| 折旧和摊销 | 1.4万 USD | 2.5万 USD | 4.5万 USD | 5.7万 USD | — |
| 营业利润 | 1163.2万 USD | −1257.1万 USD | −468.1万 USD | −386万 USD | −94.39万 USD |
| 净利润 | −1191.2万 USD | −1644.3万 USD | −494.2万 USD | −321.5万 USD | −75.52万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年5月29日 | 1:10 | — | — |
股票拆分 | 2025年7月29日 | 1:15 | — | — |
股票拆分 | 2024年11月29日 | 1:9 | — | — |
已生效 2026年5月29日
1:10
已生效 2025年7月29日
1:15
已生效 2024年11月29日
1:9
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
